Stay up to date on current diabetes themes, proved therapeutic options, and knowledge resources and tools for you and your patients & find detailed information on Novo Nordisk diabetes products: Tresiba^® (insulin degludec), Victoza^® (liraglutide injection), Levemir^® (insulin detemir), NovoMix^® (biphasic insulin aspart), NovoRapid^® (insulin aspart), and our pens & devices.

Novo Nordisk provides localized information to HCPs in the following countries:

Argentina

Australia

Brazil

Why only for Health Care Professionals

According to applicable law, only Health Care Professionals are allowed to access the product information in this section.

Information for patients and relatives

If you are a US visitor, please click here

Overview

Haemostasis management

Product information

NovoSeven®

Dosing

Storage information

Vial information

Haemostasis

Management

Blood coagulation

Educational

Key papers

Treatment guidelines

Services & links

WFH patients' leaflet

Patient story

Disease areas

Congenital haemophilia

Acquired haemophilia

Factor VII deficiency

Glanzmann's thrombasthenia

Why only for Health Care Professionals

According to applicable law, only Health Care Professionals are allowed to access the product information in this section.

Information for patients and relatives

If you are a US visitor, please click here

Overview

Growth hormone therapy overview

Pharmaceutical information

Norditropin®

Indications

GHD (Growth hormone deficiency)

GHDA (Growth hormone deficiency) in adults

SGA (Small for gestational age)

Turner syndrome

Noonan syndrome

Skeletal dysplasia

Chronic renal disease

Prader-Willi syndrome

Injection devices

Norditropin® FlexPro®

Norditropin NordiFlex®

NordiPen® with Norditropin® SimpleXx®

Norditropin® NordiLet®

Needles

NovoFine®

Programmes & support

NordiNet® (outcomes registry)

NordiScience® (HCP support)

NordiCare® (Patient support)

Our partnership with Save the Children

Patient testimonials

Testimonials

Why only for Health Care Professionals

According to applicable law, only Health Care Professionals are allowed to access the product information in this section.

Information for patients and relatives

If you are a US visitor, please click here

Overview

Our products

Introduction

Activelle®

Eviana®

Novofem®

Estrofem®

Vagifem®

Convenience & compliance

Our history in HRT

About HRT

Introduction

Symptoms & complaints

Duration of treatment

Oestrogen

Progestogen

Continuous combined HRT

Sequential combined HRT

Low-dose HRT

Why only for Health Care Professionals

According to applicable law, only Health Care Professionals are allowed to access the product information in this section.

Information for patients and relatives

If you are a US visitor, please click here

Diabetes care
Haemostasis management
Growth hormone therapy
Hormone replacement therapy

Exclusively for Health Care Professionals

Novo Nordisk provides localized information to HCPs in the following countries:

Why only for Health Care Professionals

According to applicable law, only Health Care Professionals are allowed to access the product information in this section.

Information for patients and relatives

If you are a US visitor, please click here

Overview

Haemostasis management

Product information

Haemostasis

Educational

WFH patients' leaflet

Patient story

Disease areas

Congenital haemophilia

Acquired haemophilia

Factor VII deficiency

Glanzmann's thrombasthenia

Why only for Health Care Professionals

According to applicable law, only Health Care Professionals are allowed to access the product information in this section.

Information for patients and relatives

If you are a US visitor, please click here

Overview

Growth hormone therapy overview

Pharmaceutical information

Norditropin®

Indications

GHD (Growth hormone deficiency)

GHDA (Growth hormone deficiency) in adults

SGA (Small for gestational age)

Turner syndrome

Noonan syndrome

Skeletal dysplasia

Chronic renal disease

Prader-Willi syndrome

Injection devices

Norditropin® FlexPro®

Norditropin NordiFlex®

NordiPen® with Norditropin® SimpleXx®

Norditropin® NordiLet®

Needles

NovoFine®

Programmes & support

NordiNet® (outcomes registry)

NordiScience® (HCP support)

NordiCare® (Patient support)

Our partnership with Save the Children

Patient testimonials

Testimonials

Why only for Health Care Professionals

According to applicable law, only Health Care Professionals are allowed to access the product information in this section.

Information for patients and relatives

If you are a US visitor, please click here

Overview

Our products

Convenience & compliance

Our history in HRT

About HRT

Introduction

Symptoms & complaints

Duration of treatment

Oestrogen

Progestogen

Continuous combined HRT

Sequential combined HRT

Low-dose HRT

Why only for Health Care Professionals

According to applicable law, only Health Care Professionals are allowed to access the product information in this section.

Information for patients and relatives

If you are a US visitor, please click here

Log out to deactivate menu

Careers

Overview

Available jobs

Unsolicited applications

E-mail job agent

Working at Novo Nordisk

Pages in Danish

Working in

Research & Development

Device Research & Development

Programmes

Students & Graduates

Trainees (Danish only)

Events

Facts about Novo Nordisk

Novo Nordisk in brief

The Novo Nordisk Way

Novo Nordisk Way Essentials

About Novo Nordisk Way

Our Policies

View Novo Nordisk Way Booklet

Management

Board of Directors

Executive Management

Publications & Presentations

Download centre

Changing Diabetes®

Changing Diabetes® Programmes

World Diabetes Day

Changing Possibilities in Haemophilia®

Our ambitions

HERO

World Haemophilia Day

Corporate Governance

Governance model

Shareholder Rights

Novo Nordisk Foundation

Recommendations and practices

Novo Nordisk Worldwide

Novo Nordisk in your country

About Novo Nordisk

Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.

Headquartered in Denmark, Novo Nordisk employs approximately 40,700 employees in 75 countries, and markets its products in more than 180 countries.

Novo Nordisk’s B shares are listed on NASDAQ Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO).

Home / About Novo Nordisk / Novo Nordisk Videos

Videos

Latest videos
Most viewed

Novo Nordisk Videos

Novo Nordisk CEO and President Lars Rebien Sorensen commenting on the Q1 results (04:04)

Operating profit increased by 18% in the first quarter of 2012. Novo Nordisk CEO and President Lars Rebien Sorensen commenting on the Q1 results. Duration of the video: 4:05 minutes.

Operating profit increased by 18% in the first quarter of 2012. Novo Nordisk CEO and President Lars Rebien Sorensen commenting on the Q1 results. Duration of the video: 4:05 minutes.
Hide again

Download video

Right click and select 'Save as'.
Download (720p) HD
Download (WebM) 360p
Download (Original file)

01:18

Cities Changing Diabetes (Danish...

Nearly two-thirds of all people with diabetes live in cities. It's an emergency in slow motion....
03:49

Henry - living with type II diabetes...
05:21

The one rule we have to break

This film features the 'Rule of Halves' illustrating the challenges that need to be overcome to...
03:00

Innovating diabetes care in Turkey

Diabetes is a public health crisis, and nowhere in Europe is this more evident than in Turkey...
05:18

Portrait of a Region: International...

International Operations includes 153 countries - the entire world, except for the US, Canada,...
00:35

Press backstage pass to Novo Nordisk

Recently, a diverse range of journalists across the Internal Operations sphere was welcomed at...